Compare PCT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | CNTA |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United Kingdom |
| Employees | 174 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 955.4M | 3.5B |
| IPO Year | N/A | 2021 |
| Metric | PCT | CNTA |
|---|---|---|
| Price | $5.22 | $28.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.00 | ★ $40.89 |
| AVG Volume (30 Days) | ★ 4.9M | 1.4M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $366.83 | N/A |
| Revenue Next Year | $201.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.12 | $9.60 |
| 52 Week High | $17.37 | $30.58 |
| Indicator | PCT | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 57.51 |
| Support Level | $5.12 | $24.62 |
| Resistance Level | $6.23 | $30.29 |
| Average True Range (ATR) | 0.47 | 1.71 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 4.07 | 65.83 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.